Proposed Legislation Aimed to Equalize Oral Cancer Drug Costs
Proposed federal legislation would require insurers to cover oral cancer treatments at the same levels as intravenous therapies.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Should insurance companies be required to cover oral cancer drugs the same as intravenous therapies?
Congressman Glenn Grothman reintroduced the Cancer Drug Parity Act in 2025 to mandate that health insurance plans cover oral chemotherapy options equal to IV treatments. The move follows concerns regarding how pharmacy benefit managers, which control much of the drug market, impact patient costs.
Why it matters
Patients currently often face higher out-of-pocket costs for oral medications compared to IV therapies, despite oral drugs being used to treat 30% to 40% of cancers. This bill aims to address these financial barriers for those prescribed oral treatment regimens.
Market data shows three pharmacy benefit managers control 80% of the prescription drug market, complicating drug cost structures for patients. It is currently unknown how insurance premiums might shift if coverage parity for oral cancer drugs is mandated by federal law.
The players
Glenn Grothman
A United States Congressman representing Wisconsin who is the sponsor of the Cancer Drug Parity Act.
Ted Okon
The CEO of the Community Oncology Alliance, an organization focused on the sustainability of independent oncology practices.
The details
The Cancer Drug Parity Act targets the disparity between oral and intravenous cancer treatments, requiring insurers to treat these modalities as equivalent for billing purposes. The legislation also addresses concerns regarding the role of pharmacy benefit managers, which are often owned by insurance companies, in influencing which drugs are prioritized. Supporters argue that oral chemotherapy offers a safer and more convenient alternative for patients, yet current insurance coverage policies often create financial disincentives that steer patients toward more expensive therapies.
Timeline
Glenn Grothman reintroduced the Cancer Drug Parity Act in 2025.
The target for passing the legislation is late 2026 or early 2027.
Health Landscape
The Cancer Drug Parity Act represents a targeted effort to modernize oncology insurance coverage in the United States. It follows a growing push by advocates to address how insurance-owned pharmacy benefit managers influence the accessibility of cancer treatment.
If you are managing an oncology treatment plan, this legislation addresses the potential for high out-of-pocket costs associated with oral chemotherapy. Discuss your current treatment coverage and any financial barriers you face with your oncologist or patient navigator.
The takeaway
Advocates argue that harmonizing insurance coverage for oral and IV treatments is essential to reducing the financial burden on patients. If you are struggling with the cost of cancer medications, talk to your doctor or pharmacist about available assistance programs or cost-saving support services.
What happens next
The legislative process for the Cancer Drug Parity Act is expected to move forward with a goal of passage by late 2026 or early 2027.
Further reading
For broader context on current treatment trends, see our Cancer section.
Source note: This article includes information reported by Seehafer News.
Live Poll
Should insurance companies be required to cover oral cancer drugs the same as intravenous therapies?
